Cancer stem cell-like population is preferentially suppressed by EGFR-TKIs in EGFR-mutated PC-9 tumor models

Fan Yang1, Yang Li2, Bin Liu2

  • 1Department of Immunology, Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Huanhuxi Road, Tiyuanbei, Hexi District, Tianjin 300060, People's Republic of China; Sichuan Lung Cancer Institute, Sichuan Lung Cancer Center, West China School of Medicine/West China Hospital, Sichuan University, No.37 Guoxue Lane, Wuhou District, Chengdu 610041, People's Republic of China; Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, No.154 Anshan Street, Heping District, Tianjin 300052, People's Republic of China.

Experimental Cell Research
|November 21, 2017
PubMed
Abstract

Insights

Epidermal growth factor receptor (EGFR) activates β-catenin signaling, a key pathway in lung cancer. EGFR inhibitors reduce cancer stem cells by targeting this interaction, offering new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling Pathways

Background:

  • Epidermal growth factor receptor (EGFR) and Wnt/β-catenin signaling are crucial for lung cancer development and regeneration.
  • The precise mechanisms of crosstalk between EGFR and β-catenin signaling are not fully understood.

Purpose of the Study:

  • To investigate the interaction between EGFR and the β-catenin signaling pathway.
  • To explore the role of this crosstalk in lung cancer, particularly in EGFR-mutated cells.

Main Methods:

  • Utilized EGFR-mutated PC-9 lung cancer cells.
  • Investigated the role of the PtdIns3K/AKT pathway in EGFR-mediated β-catenin activation.
  • Employed EGFR tyrosine kinase inhibitors (EGFR-TKIs) and RNA interference for β-catenin depletion.
  • Used a nude mice transplantation model and side population (SP) cell sorting.

Main Results:

  • EGFR activation leads to potent β-catenin activation, dependent on the PtdIns3K/AKT pathway.
  • EGFR-TKIs inhibit EGFR autophosphorylation, downstream signaling, and β-catenin, reducing cancer stem-like cells (CSCs).
  • β-catenin depletion significantly reduced CSCs in vitro and in vivo, decreasing tumor cell migration.

Conclusions:

  • EGFR signaling potently activates β-catenin in lung cancer cells.
  • Targeting β-catenin in combination with EGFR-TKIs may be a promising therapeutic strategy for non-small cell lung cancer (NSCLC).
  • Further research into β-catenin's role in EGFR-TKI treatment resistance is warranted.